Nicotine pouches and smokeless tobacco, explained

Nicotine pouches contain no tobacco leaf. They hold nicotine — often derived from tobacco, sometimes synthesised — plus plant fibers, sweeteners, flavoring and pH adjusters, in a small white fabric pouch placed between the lip and gum. Nothing is spat, and nothing is inhaled. Zyn, On! and Velo are the leading brands.

Snus is a Swedish moist tobacco product: pasteurized ground tobacco, in a pouch or loose, also placed under the lip and not spat. It contains tobacco leaf, and the pasteurization process produces lower levels of tobacco-specific nitrosamines than American-style products.

Traditional American smokeless tobacco covers moist snuff or dip, which is fermented and generally requires spitting, chewing tobacco in loose leaf or plug form, and dry snuff. These are the products with the longest and best-documented harm record in the United States, including oral and pancreatic cancer.

The distinction is not pedantry. Cancer risk in smokeless tobacco is driven substantially by tobacco-specific nitrosamines, which are formed during curing and fermentation of tobacco leaf. A product with no tobacco leaf has a different starting point, which is the basis on which the FDA reached its Zyn decision.

It also cuts the other way: 'no tobacco' is not 'no risk', and nicotine pouch marketing leans on the phrase in ways that invite exactly that misreading.

In January 2025 the FDA issued marketing granted orders for 20 Zyn nicotine pouch products, marketed by Swedish Match, a subsidiary of Philip Morris International. It was the first authorization for the nicotine pouch category.

The authorized products cover ten flavors — Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint and Wintergreen — in 3 mg and 6 mg strengths. Notably, none is tobacco-flavored, which makes this a substantially broader flavor authorization than anything the FDA had granted in the vape category at that point.

The FDA subsequently authorized 20 Zyn products to be marketed with a specific modified risk claim: that using Zyn instead of cigarettes puts a user at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis. That is a narrowly worded comparative claim, and its precise wording is the authorization — a manufacturer may not restate it more loosely.

The authorization is restricted to adults 21 and over and carries marketing controls intended to limit youth exposure.

As with every tobacco product, authorization is not approval and does not mean the product is safe. The FDA says this explicitly. What it means is that the agency concluded permitting these specific products was appropriate for the protection of public health, on a population-level assessment weighing adult smokers switching against non-smokers starting.

Other pouch products have followed, including an authorization for Helix Innovations' On! PLUS range in December 2025. The category now has a functioning legal pathway, which distinguishes it sharply from the disposable vape market.

The comparative claim is the strong part: for an adult who smokes and switches completely, the evidence supported a lower risk of the specific diseases named. That conclusion is about a comparison with cigarettes, not about absolute safety.

Oral health effects are the best-documented direct harm. Holding a pouch against the same gum tissue repeatedly causes gum recession as the tissue wears away, and the pouch site accumulates localized plaque, which over time contributes to cavities and decay. Rotating placement helps but does not eliminate it. Dentists see this, and it is the most commonly reported real-world problem.

Nicotine dependence is the second. Pouches deliver nicotine efficiently through the oral mucosa, are usable anywhere without smell or visible signal, and consequently are easy to use far more often than a smoking habit allowed. Several public health commentators have noted that the absence of any social friction is precisely what makes the consumption pattern hard to self-monitor.

Nicotine's cardiovascular effects apply: raised heart rate and blood pressure, which matters for people with existing cardiovascular disease. NIH-published research has raised specific concerns about adolescent cardiovascular effects, including early endothelial dysfunction and hypertension risk, alongside the established evidence that adolescent nicotine exposure harms brain development.

Youth use is real and growing. The 2024 National Youth Tobacco Survey found 1.8 percent of middle and high school students using nicotine pouches — around 480,000 students — and social media promotion of pouches to young people has drawn regulatory and congressional attention.

Long-term data does not exist for pouches specifically. They are a recent product category, and the Swedish snus evidence base, while genuinely informative, is about a different product used by a different population under a different regulatory regime.

Nicotine pouches are regulated tobacco products under FDA authority, including those using synthetic nicotine — Congress closed the synthetic nicotine gap in 2022, so 'tobacco-free nicotine' is not outside the regime.

The federal minimum age of sale is 21, with no exceptions, and applies to pouches, snus, dip, chewing tobacco and snuff alike.

Selling a nicotine pouch product without a marketing granted order is unlawful, exactly as with vapes. Many products on sale do not have one. The Zyn and On! PLUS authorizations cover specific listed products, not entire brand ranges.

State flavored tobacco restrictions generally reach smokeless products and pouches, so a flavor authorized federally may still be unlawful to sell in Massachusetts or California, or in a locality with its own ordinance.

Smokeless products fall outside clean indoor air laws, since nothing is emitted — the reason pouches are usable where smoking and vaping are not. Private rules may still prohibit them, and some employers and venues do.

PACT Act shipping rules apply to smokeless tobacco, including the USPS mailing restriction and the age verification and adult-signature delivery requirements.